Group items tagged

Despite the pervasive nature of pain, affecting 93% of the global population annually and leaving one in three individuals in daily discomfort, there exists a concerning reluctance to address and manage pain effectively. This leads to a heightened burden of suffering among people worldwide. Join our complimentary 1-hour Pain Management Webinar, meticulously crafted to equip you and your team with vital strategies to comprehend, address, and alleviate pain in your patients' lives. Delve into topics such as the pharmacist's evolving role, the significance of timely pain treatment, and initiatives like Haleon's #ListenToPain campaign. This webinar is tailored for pharmacists in GB, especially those in community, practice, PCN, and hospital settings. Don't miss this chance to enhance patient care and contribute positively to pain management. Register now to reserve your spot!

Women accounted for 62 per cent of GPhC registrants in 2019, according to the Royal Pharmaceutical Society. Despite representing the majority of pharmacists in the UK, only 2 per cent of women are pharmacy business owners compared with 13 per cent of men. Also, the majority of senior pharmacy leadership positions are held by men, with research showing that only 36 per cent of senior pharmacy leaders are women. Sobha Sharma Kandel, superintendent pharmacist and co-owner of Neem Tree Pharmacy, Abbey Wood, London, quoted these statistics while shedding light on the representation of female leaders in the field of pharmacy. So, what is stopping women from reaching leadership positions in the profession? According to Sobha, the barriers hindering female pharmacists from attaining leadership positions include: Gender Bias and Stereotypes Lack of Representation and Role Models Glass Ceiling and Double Standards Work-Life Balance Challenges Imposter Syndrome Unequal Access to Opportunities Negotiation and Advocacy Challenges "There also continue to be gender and ethnicity pay gaps affecting women in pharmacy," said Sobha, who has been advocating for women in pharmacy by being a part of the Female Pharmacy Leaders Network.

In a significant development, the British Medical Association's (BMA) consultants committee has voted to accept the government's offer on pay for senior doctors in England, along with proposed reforms to the Review Body on Doctors' and Dentists' Remuneration (DDRB). This decision follows a prolonged dispute between consultants and the government, which spanned over a year, involving unprecedented industrial actions. Committee Chair Vishal Sharma described the agreement as "the end of the beginning" in consultants' endeavors to restore their pay levels to those of 2008. Stressing the importance of the review body's independence in averting future pay disputes, Sharma emphasized the imperative role of utilizing this autonomy effectively. A staggering 83% of consultants participating in the three-week referendum voted in favor of accepting the offer, signaling a widespread endorsement of the agreement within the profession.

In a surprising move that has divided the pharmacy profession, the General Pharmaceutical Council (GPhC) has sanctioned hundreds of pharmacies to allow patients to self-select certain Pharmacy (P) medicines, a decision met with strong opposition from the Royal Pharmaceutical Society (RPS) as well as from the Pharmacy Defense Association (PDA). In a statement, RPS shared that at a board meeting held on 19th June, they expressed "disappointment" over what they described as a lack of prior consultation and comprehensive communication from the GPhC regarding the implications of this policy shift. They argue that allowing patients to self-select certain P medicines could potentially jeopardize established professional guidelines and compromise the role of pharmacists in ensuring safe medication use. "Enabled by the General Pharmaceutical Council, we understand that hundreds of pharmacies, from large multiples to small independents, have been approved by the regulator to enable patients to self-select certain P medicines," the statement said.

Change is sweeping through Westminster as the newly elected Labour government makes strategic cabinet appointments following their landslide victory in the general election held on Thursday, July 4. With Sir Keir Starmer stepping in as the new Prime Minister and Wes Streeting assuming the Secretary of State for Health and Social Care role, the announcement of Karin Smyth and Stephen Kinnock as health ministers on Monday marked a pivotal moment in Labour's healthcare agenda. Who is the new Minister of State for Health? Karin Smyth, the Labour MP for Bristol South, has been appointed as Minister of State for Health. Smyth has a robust background in healthcare, having served as a shadow spokesperson on health since December 2021. Her previous roles include Shadow Minister for Northern Ireland and Shadow Deputy Leader of the House of Commons. Before her parliamentary career, Smyth worked as an NHS Manager and held a non-executive director position at an NHS Trust.

A total of 7,599 whooping cough cases have been recorded in England from January to May 2024, according to new data released by the UK Health Security Agency (UKHSA). In January 2024, there were 555 cases, followed by 920 in February, 1,427 in March, 2,106 in April, and 2,591 in May. While the majority of cases (over 53 per cent) occurred in individuals aged 15 years or older, who typically experience milder symptoms, a significant number (262) were reported in babies under 3 months old, who are at the highest risk of severe complications and death from whooping cough. Since the outbreak began in November last year, there have been nine infant deaths (one in December 2023 and eight between January and May 2024). Whooping cough, or pertussis, is a bacterial infection affecting the lungs. This cyclical disease peaks every 3 to 5 years, with the last increase seen in 2016.

Community Pharmacy England (CPE) has notified pharmacy teams that starting 1 August 2024, three Hormone Replacement Therapy (HRT) medicines will be discontinued and will no longer be covered under the NHS HRT Prescription Prepayment Certificate (HRT PPC) scheme. These are Bedol® 2mg tablets, Climanor® 5mg tablets and Clinorette® tablets. Since Climanor® 5mg tablets have been discontinued, Medroxyprogesterone 5mg tablets will also be removed from the HRT PPC list, as this generic product is no longer available as a licensed HRT medicine. The CPE also noted that Provera® 5mg tablets, being an unlicensed HRT medicine, are not covered by the HRT PPC. Pharmacy staff are advised to check the NHS Business Services Authority (NHSBSA) website for the most current list of HRT medicines covered by the HRT PPC. The CPE has updated its HRT PPC medicines list to reflect these changes, which will also be updated in Part XVI of the August 2024 Drug Tariff.